Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L, van Beek AA, de Ruiter V, Doukas M, Wei J, Fisher TS, Ching K, Yang W, van Loon K, Boor PPC, Rakké YS, Noordam L, Doornebosch P, Grünhagen D, Verhoef K, Polak WG, IJzermans JNM, Ni I, Yeung YA, Salek-Ardakani S, Sprengers D, Kwekkeboom J. Campos Carrascosa L, et al. Among authors: ni i. J Immunother Cancer. 2020 Sep;8(2):e000816. doi: 10.1136/jitc-2020-000816. J Immunother Cancer. 2020. PMID: 32900860 Free PMC article.
An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
Yeung YA, Krishnamoorthy V, Dettling D, Sommer C, Poulsen K, Ni I, Pham A, Chen W, Liao-Chan S, Lindquist K, Chin SM, Chunyk AG, Hu W, Sasu B, Chaparro-Riggers J, Djuretic I. Yeung YA, et al. Among authors: ni i. Mol Ther. 2020 Mar 4;28(3):889-900. doi: 10.1016/j.ymthe.2019.12.014. Epub 2020 Jan 14. Mol Ther. 2020. PMID: 31981494 Free PMC article.
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y, Carrascosa LC, Yeung YA, Chu ML, Yang W, Djuretic I, Pappas DC, Zeytounian J, Ge Z, de Ruiter V, Starbeck-Miller GR, Patterson J, Rigas D, Chen SH, Kraynov E, Boor PP, Noordam L, Doukas M, Tsao D, Ijzermans JN, Guo J, Grünhagen DJ, Erdmann J, Verheij J, van Royen ME, Doornebosch PG, Feldman R, Park T, Mahmoudi S, Dorywalska M, Ni I, Chin SM, Mistry T, Mosyak L, Lin L, Ching KA, Lindquist KC, Ji C, Londono LM, Kuang B, Rickert R, Kwekkeboom J, Sprengers D, Huang TH, Chaparro-Riggers J. Xu Y, et al. Among authors: ni i. Cancer Immunol Res. 2021 Oct;9(10):1141-1157. doi: 10.1158/2326-6066.CIR-21-0058. Epub 2021 Aug 10. Cancer Immunol Res. 2021. PMID: 34376502
CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus.
Andreata F, Moynihan KD, Fumagalli V, Di Lucia P, Pappas DC, Kawashima K, Ni I, Bessette PH, Perucchini C, Bono E, Giustini L, Nguyen HC, Chin SM, Yeung YA, Gibbs CS, Djuretic I, Iannacone M. Andreata F, et al. Among authors: ni i. Sci Transl Med. 2024 Jan 10;16(729):eadi1572. doi: 10.1126/scitranslmed.adi1572. Epub 2024 Jan 10. Sci Transl Med. 2024. PMID: 38198572
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity.
Moynihan KD, Kumar MP, Sultan H, Pappas DC, Park T, Chin SM, Bessette P, Lan RY, Nguyen HC, Mathewson ND, Ni I, Chen W, Lee Y, Liao-Chan S, Chen J, Schumacher TNM, Schreiber RD, Yeung YA, Djuretic IM. Moynihan KD, et al. Among authors: ni i. Cancer Discov. 2024 Jul 1;14(7):1206-1225. doi: 10.1158/2159-8290.CD-23-1266. Cancer Discov. 2024. PMID: 38563906 Free PMC article.
Synthetic antibodies designed on natural sequence landscapes.
Zhai W, Glanville J, Fuhrmann M, Mei L, Ni I, Sundar PD, Van Blarcom T, Abdiche Y, Lindquist K, Strohner R, Telman D, Cappuccilli G, Finlay WJ, Van den Brulle J, Cox DR, Pons J, Rajpal A. Zhai W, et al. Among authors: ni i. J Mol Biol. 2011 Sep 9;412(1):55-71. doi: 10.1016/j.jmb.2011.07.018. Epub 2011 Jul 23. J Mol Biol. 2011. PMID: 21787786
52 results